PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:MD • US58502B1061
20.86 USD
-0.04 (-0.19%)
At close: Feb 4, 2026
20.86 USD
0 (0%)
After Hours: 2/4/2026, 8:04:00 PM
Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 102 industry peers in the Health Care Providers & Services industry. MD has only an average score on both its financial health and profitability. MD scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make MD a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- MD had positive earnings in the past year.
- MD had a positive operating cash flow in the past year.
- In multiple years MD reported negative net income over the last 5 years.
- In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of MD (7.37%) is better than 89.22% of its industry peers.
- The Return On Equity of MD (18.21%) is better than 86.27% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 10.25%, MD is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
- MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.16%.
- The 3 year average ROIC (7.83%) for MD is below the current ROIC(10.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
- The Profit Margin of MD (8.44%) is better than 89.22% of its industry peers.
- MD's Operating Margin of 12.20% is amongst the best of the industry. MD outperforms 83.33% of its industry peers.
- In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
- MD has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MD has more shares outstanding
- The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.15 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of MD (2.15) is comparable to the rest of the industry.
- The Debt to FCF ratio of MD is 2.20, which is a good value as it means it would take MD, 2.20 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 2.20, MD is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
- MD has a Debt/Equity ratio of 0.65. This is a neutral value indicating MD is somewhat dependend on debt financing.
- MD has a Debt to Equity ratio (0.65) which is comparable to the rest of the industry.
- Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.15 |
ROIC/WACC1.16
WACC8.86%
2.3 Liquidity
- MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a better Current ratio (1.83) than 71.57% of its industry peers.
- A Quick Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
- With a decent Quick ratio value of 1.83, MD is doing good in the industry, outperforming 74.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 56.92% over the past year.
- Measured over the past years, MD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.01% on average per year.
- The Revenue has decreased by -4.21% in the past year.
- MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
- The Earnings Per Share is expected to grow by 7.64% on average over the next years.
- The Revenue is expected to grow by 2.71% on average over the next years.
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 10.23 indicates a reasonable valuation of MD.
- Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 90.20% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.25, MD is valued rather cheaply.
- With a Price/Forward Earnings ratio of 9.26, the valuation of MD can be described as very reasonable.
- Based on the Price/Forward Earnings ratio, MD is valued cheaper than 91.18% of the companies in the same industry.
- MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.23 | ||
| Fwd PE | 9.26 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MD is valued cheaply inside the industry as 85.29% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 90.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.55 | ||
| EV/EBITDA | 7.03 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MD has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as MD's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y22.97%
EPS Next 3Y16.76%
5. Dividend
5.1 Amount
- No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
20.86
-0.04 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-19 2026-02-19/amc
Inst Owners98.9%
Inst Owner Change0.65%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.79B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (10.83%)
Short Float %3.62%
Short Ratio3.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)36.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.45%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.23 | ||
| Fwd PE | 9.26 | ||
| P/S | 0.93 | ||
| P/FCF | 6.55 | ||
| P/OCF | 6.18 | ||
| P/B | 2.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.03 |
EPS(TTM)2.04
EY9.78%
EPS(NY)2.25
Fwd EY10.8%
FCF(TTM)3.18
FCFY15.26%
OCF(TTM)3.38
OCFY16.19%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.23
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.15 |
F-Score8
WACC8.86%
ROIC/WACC1.16
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 9 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.23 and the Price/Book (PB) ratio is 2.01.